A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages

Michael Theisen; Will Roeffen; Susheel K Singh; Gorm Andersen; Linda Amoah; Marga van de Vegte-Bolmer; Theo Arens; Régis Wendpayangde Tiendrebeogo; Sophie Jones; Teun Bousema; Bright Adu; Morten Hanefeld Dziegiel; Michael Christiansen; Robert Sauerwein

doi:10.1016/j.vaccine.2014.03.020

A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages

Michael Theisen, Will Roeffen, Susheel K Singh, Gorm Andersen, Linda Amoah, Marga van de Vegte-Bolmer, Theo Arens, Régis Wendpayangde Tiendrebeogo, Sophie Jones, Teun Bousema, Bright Adu, Morten Hanefeld Dziegiel, Michael Christiansen, Robert Sauerwein

66 Citations (Scopus)

Abstract

Effective control and eventual eradication of malaria drives the imperative need for clinical development of a malaria vaccine. Asexual parasite forms are responsible for clinical disease and death while apathogenic gametocytes are responsible for transmission from man to mosquito. Vaccines that combine antigens from both stages may provide direct protection and indirect benefit by reducing the force of infection. We constructed a chimeric antigen composed of a fragment of the Plasmodium falciparum (Pf) glutamate-rich protein fused in frame to a correctly folded fragment of Pfs48/45. The chimera was produced in Lactococcus lactis and induced robust antibody responses in rodents to the individual components. Specific antibodies showed strong transmission blocking activity against multiple Pf-strains in the standard membrane feeding assay and functional activity against asexual stages in the antibody dependent cellular inhibition assay. The combined data provide a strong rationale for entering the next phase of clinical grade production and testing.

Original language	English
Journal	Vaccine
Volume	32
Issue number	22
Pages (from-to)	2623–2630
Number of pages	8
ISSN	0264-410X
DOIs	https://doi.org/10.1016/j.vaccine.2014.03.020
Publication status	Published - 7 May 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2014.03.020

Cite this

Theisen, M., Roeffen, W., Singh, S. K., Andersen, G., Amoah, L., van de Vegte-Bolmer, M., Arens, T., Tiendrebeogo, R. W., Jones, S., Bousema, T., Adu, B., Dziegiel, M. H., Christiansen, M., & Sauerwein, R. (2014). A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine, 32(22), 2623–2630. https://doi.org/10.1016/j.vaccine.2014.03.020

Theisen, M, Roeffen, W, Singh, SK, Andersen, G, Amoah, L, van de Vegte-Bolmer, M, Arens, T, Tiendrebeogo, RW, Jones, S, Bousema, T, Adu, B, Dziegiel, MH, Christiansen, M & Sauerwein, R 2014, 'A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages', Vaccine, vol. 32, no. 22, pp. 2623–2630. https://doi.org/10.1016/j.vaccine.2014.03.020

@article{2c5275b9cb744137af5d782f4354bfb4,

title = "A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages",

abstract = "Effective control and eventual eradication of malaria drives the imperative need for clinical development of a malaria vaccine. Asexual parasite forms are responsible for clinical disease and death while apathogenic gametocytes are responsible for transmission from man to mosquito. Vaccines that combine antigens from both stages may provide direct protection and indirect benefit by reducing the force of infection. We constructed a chimeric antigen composed of a fragment of the Plasmodium falciparum (Pf) glutamate-rich protein fused in frame to a correctly folded fragment of Pfs48/45. The chimera was produced in Lactococcus lactis and induced robust antibody responses in rodents to the individual components. Specific antibodies showed strong transmission blocking activity against multiple Pf-strains in the standard membrane feeding assay and functional activity against asexual stages in the antibody dependent cellular inhibition assay. The combined data provide a strong rationale for entering the next phase of clinical grade production and testing.",

author = "Michael Theisen and Will Roeffen and Singh, {Susheel K} and Gorm Andersen and Linda Amoah and {van de Vegte-Bolmer}, Marga and Theo Arens and Tiendrebeogo, {R{\'e}gis Wendpayangde} and Sophie Jones and Teun Bousema and Bright Adu and Dziegiel, {Morten Hanefeld} and Michael Christiansen and Robert Sauerwein",

note = "Copyright {\textcopyright} 2014. Published by Elsevier Ltd.",

year = "2014",

month = may,

day = "7",

doi = "10.1016/j.vaccine.2014.03.020",

language = "English",

volume = "32",

pages = "2623–2630",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "22",

}

TY - JOUR

T1 - A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages

AU - Theisen, Michael

AU - Roeffen, Will

AU - Singh, Susheel K

AU - Andersen, Gorm

AU - Amoah, Linda

AU - van de Vegte-Bolmer, Marga

AU - Arens, Theo

AU - Tiendrebeogo, Régis Wendpayangde

AU - Jones, Sophie

AU - Bousema, Teun

AU - Adu, Bright

AU - Dziegiel, Morten Hanefeld

AU - Christiansen, Michael

AU - Sauerwein, Robert

PY - 2014/5/7

Y1 - 2014/5/7

N2 - Effective control and eventual eradication of malaria drives the imperative need for clinical development of a malaria vaccine. Asexual parasite forms are responsible for clinical disease and death while apathogenic gametocytes are responsible for transmission from man to mosquito. Vaccines that combine antigens from both stages may provide direct protection and indirect benefit by reducing the force of infection. We constructed a chimeric antigen composed of a fragment of the Plasmodium falciparum (Pf) glutamate-rich protein fused in frame to a correctly folded fragment of Pfs48/45. The chimera was produced in Lactococcus lactis and induced robust antibody responses in rodents to the individual components. Specific antibodies showed strong transmission blocking activity against multiple Pf-strains in the standard membrane feeding assay and functional activity against asexual stages in the antibody dependent cellular inhibition assay. The combined data provide a strong rationale for entering the next phase of clinical grade production and testing.

AB - Effective control and eventual eradication of malaria drives the imperative need for clinical development of a malaria vaccine. Asexual parasite forms are responsible for clinical disease and death while apathogenic gametocytes are responsible for transmission from man to mosquito. Vaccines that combine antigens from both stages may provide direct protection and indirect benefit by reducing the force of infection. We constructed a chimeric antigen composed of a fragment of the Plasmodium falciparum (Pf) glutamate-rich protein fused in frame to a correctly folded fragment of Pfs48/45. The chimera was produced in Lactococcus lactis and induced robust antibody responses in rodents to the individual components. Specific antibodies showed strong transmission blocking activity against multiple Pf-strains in the standard membrane feeding assay and functional activity against asexual stages in the antibody dependent cellular inhibition assay. The combined data provide a strong rationale for entering the next phase of clinical grade production and testing.

U2 - 10.1016/j.vaccine.2014.03.020

DO - 10.1016/j.vaccine.2014.03.020

M3 - Journal article

C2 - 24662702

SN - 0264-410X

VL - 32

SP - 2623

EP - 2630

JO - Vaccine

JF - Vaccine

IS - 22

ER -

A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this